Warburg Pincus hires Francesco Granata as executive-in-residence
This article was originally published in Scrip
Leading private equity firm Warburg Pincus has appointed Dr Francesco Granata an executive-in-residence focusing on the healthcare sector. Dr Granata, based in London, will support the firm in the identification and evaluation of new investments in the biopharmaceutical sector, particularly in Europe, and provide strategic counsel across the firm's global healthcare portfolio. Dr Granata has over 35 years' experience in the pharmaceutical and biotech industries, having most recently served as executive vice-president at Biogen Idec.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.